Trodelvy

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4**.**

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ Same as Requesting Provider
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ Same as Referring Provider ❑ Same as Requesting Provider
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical (POS Code 24)*
❑ *Home (POS Code 12)*
❑ *Off Campus Outpatient Hospital (POS Code 19)*
❑ *On Campus Outpatient Hospital (POS Code 22)*
❑ *Office (POS Code 11)*

Drug Information:

Strength/Measure _____ *Units* ❑ ml ❑ Gm ❑ mg ❑ ea ❑ Un

Directions(sig) _____ *Route of administration* _____

Dosing frequency _____

What is the ICD-10 code? _____

Send completed form to: Priority Partners Fax: 1-866-212-4756

Priority Partners ● 7231 Parkway Drive Suite 100 ● Hanover, MD 21076
Phone: 888-819-1043 ● Fax: 1-866-212-4756 ● www.hopkinshealthplans.org

Criteria Questions:

1. What is the diagnosis?

❒ Breast cancer, *Continue to 2*

❒ Urothelial carcinoma - Bladder cancer, *Continue to 2*

❒ Urothelial carcinoma - Primary Carcinoma of the Urethra, *Continue to 2*

❒ Urothelial carcinoma - Upper Genitourinary Tract Tumors, *Continue to 2*

❒ Urothelial carcinoma - Urothelial Carcinoma (UC) of the Prostate, *Continue to 2*

❒ Other, please specify. _____, *Continue to 2*

2. Is the request for continuation of therapy?
❒ Yes, *Continue to 3*
❒ No, *Continue to 4*

3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

4. What is the diagnosis?

❒ Breast cancer, *Continue to 5*

❒ Urothelial carcinoma - Bladder cancer, *Continue to 16*

❒ Urothelial carcinoma - Primary Carcinoma of the Urethra, *Continue to 21*

❒ Urothelial carcinoma - Upper Genitourinary Tract Tumors, *Continue to 26*

❒ Urothelial carcinoma - Urothelial Carcinoma (UC) of the Prostate, *Continue to 26*

5. Will the requested drug be used as a single agent?
❒ Yes, *Continue to 6*
❒ No, *Continue to 6*

6. Which of the following applies to the patient's disease?

❒ Triple negative breast cancer, *Continue to 7*

❒ The cancer cells are hormone receptor positive, *Continue to 10*

❒ Other, please specify. _____, *No further questions*

7. Does the patient have a diagnosis of triple-negative breast cancer confirmed by the breast cancer cells testing negative for ALL of the following receptors: A) human epidermal growth factor receptor 2 (HER2), B) estrogen, and C) progesterone? ***ACTION REQUIRED***: Please submit test results confirming triple negative breast cancer.

❒ Yes ***ACTION REQUIRED****: Submit supporting documentation, Continue to 8*

❒ No ***ACTION REQUIRED****: Submit supporting documentation, Continue to 8*

❒ Unknown, *Continue to 8*

8. Has the patient received at least two prior therapies, with at least one line for metastatic disease?
❒ Yes, *Continue to 9*
❒ No, *Continue to 9*

9. In which clinical setting will the requested drug be used?

❒ Recurrent disease, *No further questions*

❒ Unresectable disease, *No further questions*

❒ Metastatic disease, *No further questions*

❒ The patient had no response to preoperative systemic therapy, *No further questions*

❒ Other, please specify. _____, *No further questions*

10. Is the human epidermal growth factor receptor 2 (HER2)-negative? ***ACTION REQUIRED***: If Yes, please submit test results confirming status of human epidermal growth factor receptor 2 (HER2).

❒ Yes ***ACTION REQUIRED****: Submit supporting documentation, Continue to 11*

❒ No, *Continue to 11*

❒ Unknown, *Continue to 11*

11. Has the patient received prior treatment with endocrine therapy (e.g., anastrozole [Arimidex], letrozole [Femara], fulvestrant [Faslodex])?

❒ Yes, *Continue to 12*

❒ No, *Continue to 12*

12. Has the patient received prior treatment with a CDK4/6 inhibitor (e.g., abemaciclib [Verzenio], palbociclib [Ibrance], ribociclib [Kisqali])?

❒ Yes, *Continue to 13*

❒ No, *Continue to 13*

13. Has the patient received prior treatment with at least two lines of chemotherapy (including a taxane) at least one of which was in the metastatic setting?

❒ Yes, *Continue to 14*

❒ No, *Continue to 15*

14. Is the patient a candidate for fam-trastuzumab deruxtecan-nxki (Enhertu)?

❒ Yes, *Continue to 15*

❒ No, *Continue to 15*

15. What is the clinical setting in which the requested drug will be used?

❒ Recurrent unresectable disease, *No further questions*

❒ Metastatic disease, *No further questions*

❒ No response to preoperative systemic therapy, *No further questions*

❒ Other, please specify. _____, *No further questions*

16. Will the requested drug be used as a single agent?

❒ Yes, *Continue to 17*

❒ No, *Continue to 17*

17. What is the place in therapy in which the requested drug be used?

❒ First-line treatment, *Continue to 18*

❒ Subsequent treatment, *Continue to 18*

18. In which clinical setting will the requested drug be used?

❒ Locally advanced disease, *Continue to 19*

❒ Recurrent disease, *Continue to 19*

❒ Persistent disease, *Continue to 19*

❒ Metastatic disease, *Continue to 19*

❒ Other, please specify. _____, *Continue to 19*

19. Has the patient received a platinum-containing chemotherapy (e.g., cisplatin, carboplatin)?

❒ Yes, *Continue to 20*

❒ No, *Continue to 20*

20. Has the patient received either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor?

❒ Yes, a programmed death receptor-1 (PD-1) inhibitor (e.g., Keytruda, Opdivo), *No further questions*

❒ Yes, a programmed death-ligand 1 (PD-L1) inhibitor (e.g., Bavencio, Tecentriq), *No further questions*

❒ No, *No further questions*

21. Will the requested drug be used as a single agent?

❒ Yes, *Continue to 22*

❒ No, *Continue to 22*

22. What is the place in therapy in which the requested drug be used?

❒ First-line treatment, *Continue to 23*

❒ Subsequent treatment, *Continue to 23*

23. In which clinical setting will the requested drug be used?

❒ Locally advanced disease, *Continue to 24*

❒ Recurrent disease, *Continue to 24*

❒ Metastatic disease, *Continue to 24*

❒ Other, please specify. _____, *Continue to 24*

24. Has the patient received a platinum-containing chemotherapy (e.g., cisplatin, carboplatin)?

❒ Yes, *Continue to 25*

❒ No, *Continue to 25*

25. Has the patient received either a programmed death receptor-1 (PD-1) or a programmed death ligand 1 (PD-L1) inhibitor?

❒ Yes, a programmed death receptor-1 (PD-1) inhibitor (e.g., Keytruda, Opdivo), *No further questions*

❒ Yes, a programmed death ligand 1 (PD-L1) inhibitor (e.g., Bavencio, Tecentriq), *No further questions*

❒ No, *No further questions*

Send completed form to: Priority Partners Fax: 1-866-212-4756

26. Will the requested drug be used as a single agent?
❒ Yes, *Continue to 27*
❒ No, *Continue to 27*

27. What is the place in therapy in which the requested drug will be used?

❒ First-line treatment, *Continue to 28*

❒ Subsequent treatment, *Continue to 28*

28. In which clinical setting will the requested drug be used?

❒ Locally advanced disease, *Continue to 29*

❒ Metastatic disease, *Continue to 29*

❒ Other, please specify. _____, *Continue to 29*

29. Has the patient received a platinum-containing chemotherapy (e.g., cisplatin, carboplatin)?
❒ Yes, *Continue to 30*
❒ No, *Continue to 30*

30. Has the patient received either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor?

❒ Yes, a programmed death receptor-1 (PD-1) inhibitor (e.g., Keytruda, Opdivo), *No further questions*

❒ Yes, a programmed death-ligand 1 (PD-L1) inhibitor (e.g., Bavencio, Tecentriq), *No further questions*

❒ No, *No further questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Priority Partners Fax: 1-866-212-4756